"To view the heart this way is a distinct innovation that presents new opportunities for cures that weve made good progress toward exploring," Dr. Burnett says. The researchers were the first to harness the natural properties of the heart hormone BNP, working in partnership with scientists from the biotechnology firm, Biocon, and to formulate it so it can be taken orally, in pill form. BNPs therapeutic properties include its ability to dilate blood vessels, promote salt discharge in urine, and prevent both excessive cell growth and growth of fibrous tissues. The researchers tested the oral BNP by inducing high blood pressure in laboratory animals, and then giving them the experimental drug. Results showed that the experimental oral drug reduced the mean arterial pressure steadily over time, beginning at 30 minutes after the oral treatment was given, and continuing to reduce blood pressure for two hours, the studys endpoint.
"Clearly, this novel oral form of BNP significantly reduces mean arterial pressure in an experimental model of high blood pressure," says Dr. Burnett. "Our findings are both exciting and important because they advance an innovative strategy of orally administering BNP therapy for cardiovascular diseases such as high blood pressure."
The Heart-Kidney Link
In heart failure, the kidneys also can become impaired and salt and water retention can occur, resulting in congestion. Reduced kidney function leads to buildup of toxins in the blood that can disable a person -- and progre
'"/>
Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
27-Mar-2007